378 related articles for article (PubMed ID: 33471647)
1. Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture.
Cosman F
Endocr Pract; 2020 Jul; 26(7):777-786. PubMed ID: 33471647
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
3. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
4. Anabolic skeletal therapy for osteoporosis.
Girotra M; Rubin MR; Bilezikian JP
Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):745-54. PubMed ID: 17117299
[TBL] [Abstract][Full Text] [Related]
5. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
[TBL] [Abstract][Full Text] [Related]
6. Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO).
Silva BC; Madeira M; d'Alva CB; Maeda SS; de Holanda NCP; Ohe MN; Szejnfeld V; Zerbini CAF; de Paula FJA; Bandeira F
Arch Endocrinol Metab; 2022 Nov; 66(5):591-603. PubMed ID: 36191263
[TBL] [Abstract][Full Text] [Related]
7. Abaloparatide: A new pharmacological option for osteoporosis.
Sleeman A; Clements JN
Am J Health Syst Pharm; 2019 Jan; 76(3):130-135. PubMed ID: 30689744
[TBL] [Abstract][Full Text] [Related]
8. Treating osteoporosis to prevent fractures: current concepts and future developments.
Lorentzon M
J Intern Med; 2019 Apr; 285(4):381-394. PubMed ID: 30657216
[TBL] [Abstract][Full Text] [Related]
9. The evolving role of anabolic therapy in the treatment of osteoporosis.
Cosman F
Curr Opin Rheumatol; 2019 Jul; 31(4):376-380. PubMed ID: 31090588
[TBL] [Abstract][Full Text] [Related]
10. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
Langdahl B
Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
[TBL] [Abstract][Full Text] [Related]
11. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.
Leder BZ
Curr Osteoporos Rep; 2017 Apr; 15(2):110-119. PubMed ID: 28303448
[TBL] [Abstract][Full Text] [Related]
12. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
Reginster JY
Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
[TBL] [Abstract][Full Text] [Related]
13. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
14. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
Yang L; Kang N; Yang JC; Su QJ; Liu YZ; Guan L; Liu T; Meng XL; Wang Y; Hai Y
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2640-2668. PubMed ID: 30964193
[TBL] [Abstract][Full Text] [Related]
15. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
17. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
18. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.
Migliore A; Broccoli S; Massafra U; Bizzi E; Frediani B
Curr Med Res Opin; 2012 Mar; 28(3):467-73. PubMed ID: 22256908
[TBL] [Abstract][Full Text] [Related]
19. Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.
Cosman F; Nieves JW; Dempster DW
J Bone Miner Res; 2017 Feb; 32(2):198-202. PubMed ID: 27925287
[TBL] [Abstract][Full Text] [Related]
20. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
Miller PD; Bilezikian JP; Fitzpatrick LA; Mitlak B; McCloskey EV; Cosman F; Bone HG
Curr Med Res Opin; 2020 Nov; 36(11):1861-1872. PubMed ID: 32969719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
